TRANSFORMING a standard truck into an off road monster has been a passion project for one man and his team of genius engineers. Gregg Higgs is owner of Fab Fours, a car accessory manufacturer that has ...

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of a class of cancer drugs, the companies said on Wednesday. As part of the ...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.

A month has gone by since the last earnings report for Kymera Therapeutics, Inc. (KYMR). Shares have added about 10.9% in that time frame, outperforming the S&P 500.

Kymera has collaborative deals with both Vertex and Sanofi, totalling some $220mn upfront. The firm was initially backed by Atlas Ventures, which is still the largest shareholder.

Kymera is advancing into Phase 2 with Sanofi, which could validate protein deg approach, open up multi-billion dollar market opportunity. Read more here.

Kymera Therapeutics may have signed a $750 million deal with Gilead, but the Watertown biotech also suffered a setback in its partnership with Sanofi.

The Kymera will come in two different sizes aimed at the recreational market, with each offering a choice of two different power options. A 5’6” (1.67 m) model will come with a choice of a 5 ...

When we last checked in with Jason Woods, he’d electrified his Kymera powered body board and was aiming for a 2013 release and US$5,000 retail price. To finally get the Kymera in the hands ...